期刊
FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.819128
关键词
PI3K; Akt; mTOR pathway; targeted therapy; precision medicine; cancer; oncogenic alterations
类别
资金
- National Natural Science Foundation of China [81660755]
- Science and Technology Project of Shenzhen of China [JCYJ20170307160524377, JCYJ20190808162605484]
Cancer is a global public health issue that hinders the improvement of life expectancy worldwide. Current therapeutic options are insufficient, necessitating targeted treatments. Understanding the association between the PI3K/AKT/mTOR pathway and tumorigenesis, as well as the development of therapies targeting this pathway, is crucial for clinical decision-making.
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据